Video
Dr. Gafita on Prognostic Models for Treatment With 177Lu-PSMA-617 in mCRPC
Author(s):
Andrei Gafita, MD, discusses key takeaways from a retrospective analysis evaluating lutetium-177 PSMA-617 in patients with metastatic castration-resistant prostate cancer.
Andrei Gafita, MD, Department of Nuclear Medicine, Klinikum Rechts der Isar, Technical University Munich in Germany, discusses key takeaways from a retrospective analysis evaluating lutetium-177 PSMA-617 (177Lu-PSMA-617) in patients with metastatic castration-resistant prostate cancer (mCRPC).
During the 2020 ASCO Virtual Scientific Program, Gafita presented findings from the study, revealing that 68Ga-PSMA-11 PET/CT derived parameters served as critical prognostic markers for progression-free survival and overall survival in men with mCRPC.
These indicate that PSMA expression within the tumor is predictive of survival and treatment response, says Gafita.
Additionally, these prognostic models may inform the clinical utility, outcomes, and clinical trial designs with 177Lu-PSMA-617 therapy in mCRPC, concludes Gafita.
